A foam for the treatment of varicose veins is disclosed, comprising a sclersosant solution, e.g. polidocanol, foamed with a gas mixture which includes greater than 41% of a lipid soluble gas such as xenon. The aim is to provide a foam which may be injected into a varicose vein in large quantities because the gas component is dissipated quickly after the foam has acted on the varicose vein.
|
1. A foam comprising a liquid phase and a gas phase wherein the liquid phase comprises at least one sclerosing agent and the gas phase comprises from 41% to 100% of xenon.
2. A foam of
4. A method of treating varicose veins comprising injecting into a vein in need thereof a foam of
5. A method of
|
This application is a national stage filing under 35 U.S.C. §371 of International Application No. PCT/GB2006/001754 filed on May 12, 2006. This application claims priority of British Patent Application No. 0509824.9, filed on May 13, 2005 and British Patent Application No. 0517361.2, filed Aug. 24, 2005, all of which are incorporated herein by reference.
The present invention relates to a therapeutic foam e.g. for treatment of varicose veins.
In recent years the use of sclerosing chemicals in the form of foams has become a popular way of treating varicose veins. Foam is injected into the affected vein whilst it progress is monitored using ultrasound scanning. The process causes sclerosis and functional elimination of the vein. Other disorders such as venous malformations may also be treated this way.
Most practitioners make foam extemporaneously using ambient air as the gaseous component. As extensively discussed in copending patent applications nos. PCT/GB04/004824, PCT/GB04/004831, PCT/GB04/004846 and PCT/GB04/004848, the use of air foams is potentially harmful and, in the view of the inventors, is to be avoided. The inventors have followed the key disclosure by the Cabreras in their patent EP0656203B who first proposed a microfoam with oxygen or carbon dioxide as the gas component. Carbon dioxide and oxygen are respectively dissolved blood in or absorbed by haemoglobin, thus making both considerably more attractive than air.
There are other gases which are very soluble, e.g. nitrous oxide. Helium has also been considered since it passes easily across pulmonary gas exchange membranes and hence is exhaled from the body quickly.
The inventors have now surprisingly realised that the gas need not be soluble and need not necessarily be absorbed only by the blood: it is possible to overcome the problem of foam treatment leaving residual gas in the body by using a gas component which dissolves into tissue other than blood, e.g. the vein walls. In this context, they have conceived of the possibility of using a lipid soluble gas, e.g. one or more of the noble gases, as a substantial proportion (greater than 40%) of the gas component of the foam. The higher molecular weight noble gases, especially xenon, are known to dissolve in lipid, e.g. in cell walls. Thus it appears that these gases may be taken up by the body quickly if injected into the venous system, both into the cells of the vein walls and into the blood cells. This dual mode of uptake may give rise to very fast absorption, especially if the gas also has a degree of solubility in water as well. Speed of uptake is critical because if gas is taken up slowly, this may give the opportunity for nitrogen which is already dissolved in the blood to diffuse into the foam, potentially causing enduring bubbles. Again, this is discussed at length in the copending applications mentioned above.
According to the present invention a foam is provided comprising a liquid phase and a gas phase wherein the liquid phase comprises at least one sclerosing agent and the gas phase comprises between 41% and 100% of a gas which is lipid soluble, preferably between 50 and 100%, more preferably between 60 and 100%, still more preferably between 70 and 100%, 80 and 100% or 90 and 100%.
The lipid soluble gas may be argon, krypton or xenon or a mixture of these. The most preferred of these is xenon. Xenon is used as an anaesthetic, and its behaviour in body tissue is well understood: see for example “Xenon Anesthesia”: Lynch et al, Anesthesiology, v92, No. 3, March 2000. Xenon has the further advantage that it is moderately soluble in water (mole fraction solubility 7.9×10−5, which is three times as soluble as oxygen).
If the lipid soluble gas does not make up 100% of the gas phase, then it is preferred that the remainder of the gas phase consist essentially of oxygen, carbon dioxide or a mixture of the two.
A fume cupboard is filled with greater than 99% pure xenon gas, after placing in the cupboard a small (100 ml) beaker containing 10 ml 1% polidocanol solution, together with a small hand held electric motor with a chuck in which is mounted a small (10 mm diameter) dental brush. The motor is switched on and the speed adjusted to 12,000 r.p.m. The dental brush is then gently inserted into the liquid in the beaker, such that a vortex is formed in the surface of the liquid in the beaker. After a few seconds a foam forms, which becomes finer and more homogeneous as time goes on. After 90 seconds the brush is removed. In the beaker is a stiff, homogeneous foam whose bubbles are in the main part invisible to the naked eye (a “microfoam”). The beaker may be inverted for a few seconds without the foam falling out. 30 ml of the foam is then drawn out of the beaker using a syringe for use in the treatment of a human patient's varicose veins using methodology which is generally known in this field.
Patent | Priority | Assignee | Title |
Patent | Priority | Assignee | Title |
2630183, | |||
2724383, | |||
3698453, | |||
3767085, | |||
3955720, | Nov 15 1972 | Low pressure dispensing apparatus with air pump | |
3970219, | Mar 03 1975 | Aerosol containers for foaming and delivering aerosols and process | |
4019657, | Mar 03 1975 | Aerosol containers for foaming and delivering aerosols | |
4040420, | Apr 22 1976 | Hughes Missile Systems Company | Packaging and dispensing kit |
4127131, | Jun 20 1977 | Johnson & Johnson | Hub assembly for use in the filtration of fluids and method of making the same |
4276885, | May 04 1979 | Schering, AG | Ultrasonic image enhancement |
4292972, | Jul 09 1980 | E R SQUIBB 6 SONS, INC | Lyophilized hydrocolloio foam |
4328107, | Nov 28 1980 | Technology Holding Company | Process and apparatus for forming dispersions |
4466442, | Oct 16 1981 | Schering Aktiengesellschaft | Carrier liquid solutions for the production of gas microbubbles, preparation thereof, and use thereof as contrast medium for ultrasonic diagnostics |
4538920, | Mar 03 1983 | Minnesota Mining and Manufacturing Company | Static mixing device |
4718433, | Jan 27 1983 | SLF LIMITED PARTNERSHIP | Contrast agents for ultrasonic imaging |
5048750, | Apr 05 1988 | Supermatic Kunststoff AG | Device for producing and dispensing foam |
5064103, | May 23 1990 | RJS Industries, Inc. | Foam dispenser having a plurality of sieves |
5071379, | Jan 03 1989 | Foam production device | |
5084011, | Jan 25 1990 | Method for oxygen therapy using hyperbarically oxygenated liquid | |
5141738, | Apr 15 1983 | Schering Aktiengesellschaft | Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof |
5368231, | Mar 05 1993 | L'Oreal | Dispenser for foam under pressure |
5425366, | Feb 05 1988 | ACUSPHERE, INC | Ultrasonic contrast agents for color Doppler imaging |
5425580, | Dec 28 1990 | Altana Pharma AG | Dosage form for micro-bubble echo contrast agents |
5454805, | Mar 14 1994 | Medicine vial link for needleless syringes | |
5542935, | Dec 22 1989 | WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ASSIGNEE | Therapeutic delivery systems related applications |
5556610, | Dec 16 1992 | Bracco Suisse SA | Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method |
5623085, | Sep 23 1994 | Rohm and Haas Company | Method for reducing microfoam in a spray-applied waterborne composition |
5656200, | Jan 23 1993 | Henkel Kommanditgesellschaft auf Aktien | Foaming emulsions |
5676962, | Jun 23 1993 | British Technology Group Limited | Injectable microfoam containing a sclerosing agent |
5733572, | Dec 22 1989 | IMARX THERAPEUTICS, INC | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
5902225, | Oct 11 1994 | S C JOHNSON & SON, INC | Post foamable multiple-sequential-foaming composition |
6053364, | Oct 06 1995 | ALBÉA ALKMAAR B V | Device for dispensing an air-liquid mixture, in particular foam, and operating unit intended therefor |
6536629, | Jun 23 1999 | Airspray N.V. | Aerosol for dispensing a liquid |
6561237, | Nov 28 2000 | Alltemp Products Company Limited | Apparatus and method for urging fluid into a pressurized system |
6572873, | May 26 1999 | BTG International Limited | Generation of therapeutic microfoam |
6605066, | Sep 18 1998 | Imedex Biomateriaux | Device for forming and delivering a mixture |
6942165, | May 26 1999 | BTG International Limited | Generation of therapeutic microfoam |
7025290, | May 26 1999 | BTG International Ltd | Generation of therapeutic microfoam |
7357336, | May 26 1999 | BTG International Limited | Generation of therapeutic microfoam |
20020031476, | |||
20020056730, | |||
20020077589, | |||
20020101785, | |||
20040156915, | |||
20050002873, | |||
20060049269, | |||
20060062736, | |||
20060280690, | |||
20070003488, | |||
20070003489, | |||
20070031345, | |||
20070031346, | |||
20070104651, | |||
20080145401, | |||
20080274060, | |||
CA1232837, | |||
DE2608771, | |||
DE3048744, | |||
DE3050812, | |||
DE3417182, | |||
DE8704600, | |||
EP11381, | |||
EP54728, | |||
EP77752, | |||
EP123235, | |||
EP131540, | |||
EP217582, | |||
EP324938, | |||
EP359246, | |||
EP564505, | |||
EP586875, | |||
EP613836, | |||
EP656203, | |||
EP997396, | |||
EP1716871, | |||
ES2068151, | |||
FR1547768, | |||
FR2672038, | |||
FR2775436, | |||
GB2369996, | |||
JP1081895, | |||
JP8235664, | |||
RE38919, | Jun 21 1994 | BTG International Limited | Injectable microfoam containing a sclerosing agent |
WO24649, | |||
WO66274, | |||
WO72821, | |||
WO78629, | |||
WO2058834, | |||
WO3013475, | |||
WO2004047969, | |||
WO2005115484, | |||
WO9205806, | |||
WO9211873, | |||
WO9305819, | |||
WO9421384, | |||
WO9500120, | |||
WO9608227, | |||
WO9625194, | |||
WO9638180, | |||
WO9713585, | |||
WO9943371, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
May 12 2006 | BTG International Ltd. | (assignment on the face of the patent) | / | |||
Nov 22 2007 | JENKINS, WILLIAM JOHN | BTG International Ltd | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 020192 | /0306 | |
Dec 12 2022 | BTG International Limited | Provensis Limited | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 065731 | /0815 | |
Dec 15 2022 | Provensis Limited | Boston Scientific Medical Device Limited | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 065742 | /0268 |
Date | Maintenance Fee Events |
Mar 12 2014 | ASPN: Payor Number Assigned. |
Oct 05 2017 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
Oct 06 2021 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
Date | Maintenance Schedule |
Apr 22 2017 | 4 years fee payment window open |
Oct 22 2017 | 6 months grace period start (w surcharge) |
Apr 22 2018 | patent expiry (for year 4) |
Apr 22 2020 | 2 years to revive unintentionally abandoned end. (for year 4) |
Apr 22 2021 | 8 years fee payment window open |
Oct 22 2021 | 6 months grace period start (w surcharge) |
Apr 22 2022 | patent expiry (for year 8) |
Apr 22 2024 | 2 years to revive unintentionally abandoned end. (for year 8) |
Apr 22 2025 | 12 years fee payment window open |
Oct 22 2025 | 6 months grace period start (w surcharge) |
Apr 22 2026 | patent expiry (for year 12) |
Apr 22 2028 | 2 years to revive unintentionally abandoned end. (for year 12) |